Quarterly report pursuant to Section 13 or 15(d)

Derivative Contracts (Details)

v2.4.0.8
Derivative Contracts (Details) (USD $)
In Thousands, unless otherwise specified
Jun. 30, 2013
Dec. 31, 2012
Pharmsynthez [Member]
   
Derivative financial instruments:    
Derivative asset, fair value $ 6,795 $ 0
Neovasc common stock options/warrants [Member]
   
Derivative financial instruments:    
Derivative asset, fair value 2,319 1,872
Embedded conversion option [Member]
   
Derivative financial instruments:    
Derivative liability, fair value 74,079 0
Forward contracts [Member]
   
Derivative financial instruments:    
Derivative liability, fair value $ 2,242 [1] $ 1,294 [1]
[1] The effect on loss in the forward contracts is recorded in Accrued expenses. The effect on income in the forward contracts is recorded in Prepaid expenses and other current assets.